Fundraising FoxAlwin Capital — Full Portfolio
33 tracked investments · listed companies and verified rows first
EdiGene is a biotechnology company developing genome-editing-based therapies, including allogeneic cell therapies and in vivo RNA base editing platforms, alongside a high-throughput genome editing screening platform.
BiotechDeep TechHealthtech
Co-investorsLAVLilly Asia VenturesWI Harper Group3H Health InvestmentBioTrack CapitalIDG Capital+2 more
Neukio is a biopharmaceutical company developing iPSC-derived cell technology platforms and next-generation off-the-shelf, mass-producible immune cell products (such as NK cells) to treat solid tumors and autoimmune diseases.
BiotechDeep TechHealthtech
Liqun Wang(Founder)
Co-investorsPan-Lin CapitalIDG CapitalLilly Asia VenturesSherpa Healthcare Partners
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
23魔方久事神康元码基因博雅辑因嘉晨西海大图医疗尤卡迪康景生物心岭迈德思纳福新合生物智因东方未知君泓迅生物瑞风生物百力司康科亚医疗科越生物精锋医疗罗森博特美柏生物美立刻臻和科技臻知医学艾博生物苏博医学英盛生物菲沙基因辉大基因阿诺医药齐碳科技
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.